Tag Archive for: enzalutamide
Triplet therapy shows strongest survival benefit in mHSPC with visceral disease
/0 Comments/in Review/by MaxReal-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/0 Comments/in Retrospective studies/by MaxPhase 1/2 Trial: Targeting Resistance With SX-682 And Apalutamide or Enzalutamide
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 ENZAMET Trial: Follow-up Data After 8 Years
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxTALAPRO-2 Trial: Final OS Analisys Confirms Talazoparib + Enzalutamide Effectiveness in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPembrolizumab Plus Enzalutamide Therapy Shows No Benefit in Metastatic Castration-Resistant Prostate Cancer Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/0 Comments/in Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- LYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer July 30, 2025
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025
- FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors July 28, 2025